CA-CLICKHOUSE-INC
24.3.2023 14:01:30 CET | Business Wire | Press release
Today, ClickHouse, Inc., creators of ClickHouse online analytical processing (OLAP) database, and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, announced a partnership that will enable Alibaba Cloud to offer ClickHouse as an enterprise, first-party service on its platform. This partnership is an exclusive agreement between ClickHouse, Inc. and Alibaba Cloud in mainland China to offer a joint first-party enterprise service in APAC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230324005222/en/
Aaron Katz, Founder & CEO, ClickHouse, Inc. (Photo: Business Wire)
ClickHouse is the world's fastest and most resource-efficient analytical database, and since it was released as an open-source project in 2016, adoption has grown exponentially – globally. Organisations large and small benefit from the blazing fast speed - with peak processing performance for a single query standing at more than two terabytes per second. Put simply, you can query billions of rows in milliseconds.
As the world’s third-leading and Asia Pacific’s leading Infrastructure-as-a-Service (IaaS) provider, Alibaba Cloud provides a comprehensive suite of cloud computing services to customers worldwide, including elastic computing, database, storage, network virtualization, large-scale computing, security, management and application services. Alibaba Cloud has been named a Leader in the Gartner® Magic Quadrant™ for Cloud Database Management Systems (DBMS) for the third consecutive year in 2022.
ClickHouse allows any company to turn their data into insights and innovation in near real-time, whether it's a bank trying to detect fraud or a streaming service tracking the next blockbuster. ClickHouse users include global brands like Alibaba, Cloudflare, eBay, and Uber.
“ClickHouse is already a hugely popular analytical database in China; this partnership enables us to scale with a local partner to serve the 1000s of ClickHouse users across Asia,” said Aaron Katz, Co-founder, and CEO, ClickHouse, Inc. “We are delighted users across Asia will be able to access the same level of service and support from Alibaba Cloud that the users of ClickHouse Cloud have come to expect.”
The new enterprise ClickHouse service on Alibaba Cloud will be powered by the proprietary cloud native engine developed by ClickHouse, Inc. that includes enhanced capabilities to power cloud-native analytical workloads. Benefits of this first-party service include unmatched performance and greatly improved cost efficiency, making it possible for modern enterprises to invest more in building analytical applications. Exclusive serverless capabilities of this service greatly reduce getting-started steps for building analytical applications. These serverless capabilities could enable users to scale from 10 to 100 replicas under a second and ingest 350B records within 2 hours, allowing businesses to innovate faster in increasingly competitive markets.
Feifei Li, Vice President of Alibaba Group and President of Database Business, Alibaba Cloud Intelligence, said, “ClickHouse is already one of the most popular analytical databases running on our platform. With this partnership, we are able to offer the first official first-party ClickHouse service to our users, delivering levels of service that are demanded by migrating self-managed open-source users and enterprise IT systems of all sizes.”
About ClickHouse
ClickHouse is the world's fastest and most resource-efficient online analytical column-oriented database management system. Now offered as a secure and scalable serverless offering in the cloud, ClickHouse Cloud allows anyone to effortlessly take advantage of efficient real-time analytical processing.
Learn more at clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005222/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom